awesome read...thanks localhero, page-16

i have not reviewed the analyst report in detail, but one interesting question that arises (i think) is that the modelling essentially assumes that PRR "goes it alone" rather than doing a partnering/licencing deal.

Do you think that this is realistic?

It is at odds with the expectations of many on this forum that PRR may announce a deal of some sort with a major pharma company some time in the next few months.

Can PRR distribute the product widely without a partner?

Note that a partner would insist on a minimum of half of the revenues.

this is not downramping - it is a fair & honest question